Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
25.99
-0.24
(
-0.91% )
|
25.97
|
6,800 |
25.99
|
1,300 |
Analysis date: 29.08.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 04.07.2025.
Interest
Very strong
Very strong
Four stars since 12.08.2025.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 12.08.2025 at a price of 25.45.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 09.05.2025.
4wk Rel Perf
13.44%
13.44%
The four-week dividend-adjusted overperformance versus SP500 is 13.44%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 08.08.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.25%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.79%.
Mkt Cap in $bn
4.38
4.38
With a market capitalization between $2 & $8bn, ACADIA PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
1.89
1.89
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
14.67
14.67
The estimated PE is for the year 2028.
LT Growth
27.68%
27.68%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
91
91
For 1% of index variation, the stock varies on average by 0.91%.
Correlation
0.33
0.33
Stock movements are strongly independent of index variations.
Value at Risk
6.24
6.24
The value at risk is estimated at USD 6.24. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2013
21.05.2013